Article information
Resumo
No presente artigo, revimos os avanços mais recentes na área médica, sobretudo em áreas que têm contribuído para o progresso da ciência. Referimos os avanços nas áreas da biologia e da genética, da bioengenharia e telecomunicações, entre outros. De igual modo revimos os diversos avanços em várias áreas das patologias do aparelho respiratório mais frequentes, mais carenciadas em termos de evolução das técnicas de diagnóstico ou mais promissoras de avanços nos próximos anos.
Rev Port Pneumol 2005; XI (1): 47-61
Palavras-chave:
Avanços
doenças respiratórias
diagnóstico
tratamento
Abstract
In the present article, we reviewed the most recent advances in the medical area and areas that contributed for the advances of medical science. We relate the advances in the areas of Biology and the Genetics, Bioengineering and Telecommunications among others. We also reviewed the most relevant advances in some areas of the more frequent pathologies of the respiratory tract, particularly those that urgently need new progress in terms of new techniques of diagnosis, therapeutics or prevention measures in the next years.
Rev Port Pneumol 2005; XI (1): 47-61
Key-words:
Advances
respiratory diseases
therapeutics
diagnosis
Full text is only aviable in PDF
Bibliografia
[1.]
S. Agrawal, N.S. Thomas.
Antituberculosis drugs and new drug development.
Curr Opin Pulm Med, 7 (2001), pp. 142-147
[2.]
ATS/CDC/IDSA: Treatment of Tuberculosis.
Am J Resp Crit Care Med, 167 (2003), pp. 603-662
[3.]
M.F. Baganha.
Terapêutica substitutiva em Pneumologia.
Tratado de Pneumologia,
[4.]
P.J. Barnes.
Future advances in COPD therapy.
Respiration, 68 (2001), pp. 441-448
[5.]
P.J. Barnes.
New directions in allergic diseases: mechanism-based anti-inflammatory therapies.
J Allergy Clin Immunol, 106 (2000),
[6.]
P.J. Barnes.
New targets for future asthma therapy.
New and exploratory therapeutic agents for asthma, pp. 361
[7.]
I. Bastian, R. Stapledon.
Colebunders R Current thinking on the management of tuberculosis.
Curr Op Pulm Med, 9 (2003), pp. 186-192
[8.]
W.A. Biernacki, S.A. Kharatinov, P.J. Barnes.
Increased leukotriene B4 and 8-isoprostane in exhaled brath condensate of patients with exacerbations of COPD.
Thorax, 58 (2003), pp. 294-298
[9.]
Bunn Pajr, Soriano A, Johnson G, Heashey L. New therapeutic strategies for Lung Cancer: Biology and Molecular Biology Come of Age. Chest 200;117:163S–168S.
[10.]
A. Bush, D. Geddes.
Cystic fibrosis in adolescence.
In Eur Respir Mon, 19 (2002), pp. 225-253
[11.]
W. Busse.
Anti-immunoglobulin E, (Omalizumab) therapy in allergic astham.
Am J Resp Crit Care Med, 164 (2001), pp. 512-517
[12.]
D.N. Carney.
Lung cancer-time to move on from chemotherapy.
N Engl J Med, 346 (2002), pp. 126-128
[13.]
J.P. Cegielski, D. Chin, M.A. Espinal.
The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century.
Infectious Dis Clin North Am, 16 (2002), pp. 1-58
[14.]
J.P. Chute, T. Chen, E. Feigal, et al.
J Clin Onc, 17 (1999), pp. 1794-1801
[15.]
E.L. Corbett, C.J. Watt.
The growing burden of tuberculosis.
Global trends and Interactions with the HIV Epidemic. Arch intern Med, 163 (2003), pp. 1009-1021
[16.]
L.A.J.M. Creuwels, L.M.G. Van Golde, H.P. Haagsman.
The pulmonary surfactant system: biochemical and clinical aspects.
Lung, 175 (1997), pp. 1-39
[17.]
T.L. Croxton, G.G. Weinmann.
NHLBI Workshop Summary. Clinical Research in Chronic Obstructive Pulmonary Disease. Needs and Opportunities.
Am J Respir Crit Care Med, 167 (2003), pp. 1142-1149
[18.]
R.G. Crystal.
Research opportunities and advances in Lung Diseases.
JAMA, 285 (2001), pp. 612-618
[19.]
A.E. Curley, H.L. Halliday.
The present status of exogenous surfactant for the newborn.
Early Hum Dev, 61 (2001), pp. 67-83
[20.]
W.I. de Boer, J.K. Sont.
Monocyte chemoattractant protein-1, interleukin 8 and chronic airways inflammation in COPD.
J Pathol, 190 (2000), pp. 619-626
[21.]
J.M. Razen.
SARS-Looking back over the firt 100 days.
N Engl J Med, 349 (2003), pp. 3193-3220
[22.]
C. Dye, S. Scheele, P. Dolin.
Global burden of tuberculosis. Estimated incidence, prevalence and mortality by country.
JAMA, 282 (1999), pp. 677-686
[23.]
T. Fujiwara, H. Maeta.
Artificial surfactant therapy in hyaline membrane disease.
Lancet, 1 (1980), pp. 55-59
[24.]
S.Z. Goldhaler.
Pulmonary embolism.
N Engl J Med, 339 (1998), pp. 93-104
[25.]
J.M. Grange, A. Zumla.
Advances in the mana-gement of tuberculosis: clinical trials and beyond.
Curr Opin Pulm Med, 6 (2000), pp. 193-197
[26.]
Griffith lg, Grodzinsky AJ. Advances in Biomedical Engeneering. JAMA 285(5):556–561.
[27.]
Grootendorst DC, Gauw SA, Benschop N e col. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and COPD. Pulm Pharmacol Ther 203; 16(6):341-347
[28.]
D.W.P. Hay.
Chronic obstructive pulmomnary desease: emerging therapies.
Curr Opin Chem Biol, 4 (2000), pp. 412-419
[29.]
D.W.P. Hay, H.M. Sarau.
Interleukin-8 receptor antagonists in pulmonary diseases.
Curr Opin Pharmacol, 1 (2001), pp. 242-247
[30.]
C.I. Henschke, D.I. Mccauley, D.F. Yankelevitz, D.P. Naidich, G. Mcguinness, O.S. Mierrinen.
Early Lung Cancer Action project: overall design and findings from baseline screening.
Lancet, 354 (1999), pp. 99-105
[31.]
F.R. Hirsch, J.R. Fisher, J. Niklinsky, S. Zochbauer-Muller.
Futures developments in the treatment of lung cancer.
Lung cancer, 38 (2002), pp. S81-S85
[32.]
S.T. Holgate.
The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody.
Clin Exp Allergy, 31 (2001), pp. 1344
[33.]
S.T. Holgate, A.G. Chuchalin, J. Lotvall.
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Clin Exp Allergy, 43 (2004), pp. 632-638
[34.]
S.T. Holgate, J. Corne, P. Jardieu, R.B. Fick, C. Heusser.
Treatment of allergic airways disease with anti-IgE.
Allergy Suppl, 45 (1998), pp. 83
[36.]
P. Iyengar.
TSAO MS – Clinical revelance of molecular markers in lung cancer.
Surgical Oncology, 11 (2002), pp. 167-179
[37.]
D.E. Jorenby, S.J. Leischow, M.A. Nides.
A controlled trial of sustained-release bupropion, a nicotine patch or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 385-691
[38.]
Kejjey, et al.
Prevention of Lung Cancer. Summary of Published Evidence.
Chest, 123 (2003), pp. 50S-59S
[39.]
H.A.M. Kerstjens, H.J. Groen, W. Bij.
Recent advances:Respiratory Medicine.
BMJ, 323 (2001), pp. 1349-1353
[40.]
S.A. Kharatinov, P.J. Barnes.
Biomarkers of some pulmonary diseases in exhaled breath.
Biomarkers, 7 (2002), pp. 1-32
[41.]
M.R. Knowles.
A controlled study of adenovirus-vector-mediated gene transfer in the nasal epithelium of patients with Cystic fibrosis.
N Engl J Med, 333 (1995), pp. 823-831
[42.]
N.L. Letvin, B.R. Bloom, S.L. Hoffman.
Prospects for vaccines to protect against AIDS. Tuberculosis and Malaria.
JAMA, 285 (2001), pp. 606-611
[43.]
R.A. Matthay.
Hereditary thrombophilia and venous thromboembolism.
Am J Resp Crit Care Med, 158 (1998), pp. 1369-1373
[44.]
J.D. Merril, R.A. Ballard.
Pulmonary surfactant for neonatal respiratory disordres.
Curr Opin Pediatr, 15 (2003), pp. 149-154
[45.]
Ministério da Saúde.
Plano Nacional de Saúde, (2003),
[46.]
P. Montushci, J.V. Collins.
Am J. Resp. Crit. Care Med., 16 (2000), pp. 1175-1177
[47.]
C.J.L. Murray, A.D. Lopez.
Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study.
Lancet, 349 (1997), pp. 1498-1504
[48.]
National Institutes of Heart, Lung and Blood Institute and World Health Organization.
Global Strategy for Asthma Management and Prevention,
[49.]
National Institutes of Heart, Lung and Blood Institute and World Health Organization.
Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease,
[50.]
C. Piersimoni, C. Scarparo, P. Cichero, M.D. Pezzo, I. Covelli, G. Gesu.
Multicentre evaluation of the MB-Redox médium compared with radiometric BACTEC system, mycobacteria growth indicator tube (MGIT) and Lowenstein-Jensen médium for detection and recovery of acid-fast bacilli.
Diagn Microbiol Infect Dis, 34 (1999), pp. 293-299
[51.]
F. Rastjen, G. Doring.
Cystic fibrosis.
Lancet, 361 (2003), pp. 681-689
[52.]
H.Y. Reynolds.
Use of bronchoalveolar lavage in Humans – Past necessity and future imperative.
Lung, 178 (2000), pp. 271-293
[53.]
J.R. Riordan, J.M. Rommens, B.S. Kerem.
Science.
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, 245 (1989), pp. 1066-1073
[54.]
W. Rook Ga, G. Seah, A. Ustianowski.
M tuberculosis:immunology and vaccination.
Eur Respir J, 17 (2001), pp. 537-557
[55.]
B.K. Rubin.
Emerging therapies for Cystic Fibrosis Lung Disease.
Chest, 115 (1999), pp. 1120-1126
[56.]
Scotet V et al. Neonatal screening for cystic fibrosis in Brittany, France:assessment of 10.
[57.]
K.A. Sepkowitz.
AIDS – The First 20 Years.
N Engl J Med, 344 (2003), pp. 1764-1772
[58.]
S.A. Silbaugh, P.W. Stengel, S.L. Cockerham.
Pharmacological actions of the second generation leukotriene B4 receptor antagonist LY 29311: in vivo pulmonary studies.
Arch Pharmacol, 361 (2000), pp. 397-404
[59.]
D.L. Smith, R.D. Deshazo.
Bronchoalveolar lavage in asthma. An update and perspective.
Am Rev Respir Dis, 148 (1993), pp. 523
[60.]
D. Spina.
Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Drugs, 63 (2003), pp. 2575-2594
[61.]
C.M.C. Tempany, B.J. McNeil.
Advances in biomedical Imaging.
JAMA, 285 (2001), pp. 562-567
[62.]
A. Vecchiarelli, M. Dottorini, D. Pietrela, C. Cociani, A. Eslami, T. Todisco, F. Bistoni.
Macrophage activation by N-acetyl-cysteine in COPD patients.
Chest, 105 (1994 Mar),
[63.]
S.E. Wenzel.
New approaches to anti-inflammatory therapy for asthma.
Am J Med, 104 (1998), pp. 287
[64.]
WHO.who.int/mediacentre/factsheets/whol04/en.
[65.]
G.L. Woods.
The mycobacteriology laboratory and new diagnostic techniques.
Infectious Dis Clin North America, 16 (2002), pp. 127-143
[66.]
World Health Organization. Global DOTS expansion plan. Progress in TB control in high burden countries, 2001 WHO/CDS/STB/2001.11.2001.
[67.]
World Health Organization. Global tuberculosis Control, WHO Report 1997. Geneva. Switzerland.
[68.]
World Health Organization. Global tuberculosis Control, WHO Report 1998. Geneva. Switzerland.
[69.]
World Health Organization. Global tuberculosis Control, WHO Report 1999. Geneva. Switzerland.
[70.]
World Health Organization. Global tuberculosis Control, WHO Report 2000. Geneva. Switzerland.
[71.]
World Health Organization. Word Cancer Report. Ed Stewart BW, Kleihues P. 2003.
[72.]
H. Wu, et al.
Surfactant proteins A and D inhibit the growth of Gram negative bacteria by increasing membrane permeability.
J Clin Invest, 111 (2003), pp. 1589-1602
[73.]
X. Zheng, G.D. Roberts.
Diagnosis and susceptibility testing. In tuberculosis and nontuberculous mycobacterial.
Infections, 4th edition,
Special content about COVID-19
- Assisted mobilisation in critical patients with COVID-19
- Two years of COVID-19: Trends in rehabilitation
- Comparison of different field tests to assess the physical capacity of post-COVID-19 patients
- New insights in circulating peptidome to differentiate mild to severe COVID-19 patients: Preliminary report
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options